Schmidbauer B, Menhart K, Hellwig D, Grosse J (2017) Differentiated thyroid cancer-treatment: state of the art. Int J Mol Sci 18(6):1292. https://doi.org/10.3390/ijms18061292

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rusinek D, Chmielik E, Krajewska J, Jarzab M, Oczko-Wojciechowska M, Czarniecka A et al (2017) Current advances in thyroid cancer management. Are we ready for the epidemic rise of diagnoses? Int J Mol Sci 18(8):1817. https://doi.org/10.3390/ijms18081817

Article  CAS  PubMed  PubMed Central  Google Scholar 

INCA - Instituto Nacional de Câncer (2019) Síntese de Resultados e Comentários. https://www.inca.gov.br/estimativa/sintese-de-resultados-e-comentarios. Accessed 19 Oct 2020

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020

Article  PubMed  PubMed Central  Google Scholar 

Barres B, Kelly A, Kwiatkowski F, Batisse-Lignier M, Fouilhoux G, Aubert B et al (2019) Stimulated thyroglobulin and thyroglobulin reduction index predict excellent response in differentiated thyroid cancers. J Clin Endocrinol Metab 104(8):3462–3472. https://doi.org/10.1210/jc.2018-02680

Article  PubMed  Google Scholar 

Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A (2018) Overall survival of papillary thyroid carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J Surg 42(3):615–622. https://doi.org/10.1007/s00268-018-4479-z

Article  PubMed  PubMed Central  Google Scholar 

Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M et al (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20(12):1341–1349. https://doi.org/10.1089/thy.2010.0178

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bandeira L, Padovani RP, Ticly AL, Cury AN, Scalissi NM, Marone MMS et al (2017) Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer. Arch Endocrinol Metab 61:590–599. https://doi.org/10.1590/2359-3997000000308

Article  PubMed  PubMed Central  Google Scholar 

Abelleira E, Peñaloza MA, Jerkovich F, Bueno F, Pitoia F (2021) Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment. Arch Endocrinol Metab 65:315–321. https://doi.org/10.20945/2359-3997000000374

Article  PubMed  PubMed Central  Google Scholar 

Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. Wiley

Google Scholar 

Rosario PW, Mourão GF, Calsolari MR (2019) Definition of the response to initial therapy with radioiodine in patients with differentiated thyroid carcinoma: basal or stimulated thyroglobulin? Horm Metab Res 51(10):634–638. https://doi.org/10.1055/a-0991-0231

Article  CAS  PubMed  Google Scholar 

Jayasekara J, Jonker P, Lin JF, Engelsman AF, Wong MS, Kruijff S et al (2020) Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer. Surgery 167(1):40–45. https://doi.org/10.1016/j.surg.2019.06.048

Article  PubMed  Google Scholar 

Kelly A, Barres B, Kwiatkowski F, Batisse-Lignier M, Aubert B, Valla C et al (2019) Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients. PLoS ONE 14(8):e0221298. https://doi.org/10.1371/journal.pone.0221298

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mukhtar N, Aljamei H, Aljomaiah A, Moria Y, Alzahrani AS (2021) Natural course of the american thyroid association response to therapy statuses (Dynamic Risk Stratification) in differentiated thyroid cancer. Eur Thyroid J 10:198–207. https://doi.org/10.1159/000511708

Article  PubMed  Google Scholar 

Jammah AA, Masood A, Akkielah LA, Alhaddad S, Alhaddad MA, Alharbi M et al (2020) Utility of stimulated thyroglobulin in reclassifying low risk thyroid cancer patients’ following thyroidectomy and radioactive iodine ablation: a 7-year prospective trial. Front Endocrinol (Lausanne) 11:603432. https://doi.org/10.3389/fendo.2020.603432

Article  PubMed  Google Scholar 

Szujo S, Bajnok L, Bodis B, Nagy Z, Nemes O, Rucz K et al (2021) The prognostic role of postablative non-stimulated thyroglobulin in differentiated thyroid cancer. Cancers (Basel) 13(2):310. https://doi.org/10.3390/cancers13020310

Article  CAS  PubMed  Google Scholar 

Sunny S, Hephzibah J, Mathew D, Bondu J, Shanthly N, Oommen R (2018) Stimulated serum thyroglobulin levels versus unstimulated serum thyroglobulin in the follow-up of patients with papillary thyroid carcinoma. World J Nucl Med 17(1):41–45. https://doi.org/10.4103/wjnm.WJNM_20_17

Article  PubMed  PubMed Central  Google Scholar 

Hu H, Liang J, Zhang T, Zhao T, Lin Y (2018) Suppressed thyroglobulin performs better than stimulated thyroglobulin in defining an excellent response in patients with differentiated thyroid cancer. Nucl Med Commun 39(3):247–251. https://doi.org/10.1097/MNM.0000000000000796

Article  PubMed  Google Scholar 

Jin M, Ahn J, Lee YM, Sung TY, Song DE, Kim TY et al (2021) Clinical implications of age and excellent response to therapy in patients with high-risk differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 95(6):882–890. https://doi.org/10.1111/cen.14543

Article  PubMed  Google Scholar 

Jeon MJ, Kim M, Park S, Oh HS, Kim TY, Kim WB et al (2018) A follow-up strategy for patients with an excellent response to initial therapy for differentiated thyroid carcinoma: less is better. Thyroid 28(2):187–192. https://doi.org/10.1089/thy.2017.0130

Article  CAS  PubMed  Google Scholar 

Ha J, Kim MH, Jo K, Lim Y, Bae JS, Lee S et al (2017) Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer. Medicine 96:e7512. https://doi.org/10.1097/MD.0000000000007512

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moritani S (2017) Window resection for intraluminal cricotracheal invasion by papillary thyroid carcinoma. World J Surg 41:1812–1819. https://doi.org/10.1007/s00268-017-3927-5

Article  PubMed  Google Scholar 

Ahn J, Song E, Kim WG, Kim TY, Kim WB, Shong YK et al (2020) (2020) Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response. Endocrine 67(3):623–629. https://doi.org/10.1007/s12020-019-02142-1

Article  CAS  PubMed  Google Scholar